524723

- Company seeking shareholder approval via Postal Ballot for: - Regularization of Mr. Bidari Kotresh Anilkumar as Executive Director. - Acquisition of Sushodha Institute of Gastroenterology Private Limited for ₹15.49 Cr via share swap. - Approval of related party transactions for the acquisition. - Shifting of Registered Office. E-voting: July 15 - Aug 13, 2026.

- Approved 100% acquisition of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 Cr, discharged via share swap. SIGPL is a specialized gastroenterology hospital with growing turnover. - Approved fundraising up to ₹210 Cr via a Rights Issue of Specified Securities. - Approved change of registered office from Assam to Maharashtra. - Approved appointments of Non-Executive Directors for SMCV Management Services Private Limited.

- Approved 100% acquisition of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.48 Crores, paid by issuing 38.72 lakh equity shares at ₹40/- each. - Approved fundraising up to ₹210 Crores through a Rights Issue. - Board also approved appointments, registered office change, and a postal ballot for seeking shareholder approvals.

- The Board approved the acquisition of 100% equity shares of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.48 Crores. - The consideration for the acquisition will be discharged by issuing 3,871,854 equity shares of Arvaya Healthcare Limited at ₹40 per share through a preferential issue. - SIGPL is a specialized healthcare entity focused on gastroenterology, with a consistent increase in turnover over the last three years (₹6.36 Cr in 2023-24 to ₹8.99 Cr in 2025-26). - The company also approved a fund-raising of up to ₹210 Crores via a Rights Issue of Specified Securities. - The acquisition is expected to be completed within 12 months, aiming to achieve business synergies and expand the company's healthcare footprint.

- Board approved 100% acquisition of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.48 Cr, discharged by issuing 38.71 lakh equity shares at ₹40/share. - Approved fund raising up to ₹210 Cr via a Rights Issue of specified securities. - Approved the preferential issue of equity shares for the acquisition and board appointments.

- Approved 100% acquisition of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for ₹15.49 Crores. - Consideration for SIGPL will be discharged by issuing 38.72 lakh equity shares at ₹40/share via preferential issue. - Also approved fundraising up to ₹210 Crores via a Rights Issue of Specified Securities. - The company's registered office will change from Assam to Maharashtra.

- The company, formerly Bijoy Hans Limited, announced its name change to Arvaya Healthcare Limited. - BSE has taken on record the application, and the new name and Scrip ID 'ARVAYA' for Scrip Code 524723 will be effective from July 13, 2026.

- Board meeting scheduled for July 11, 2026, to consider acquisition of Sushodha Institute of Gastroenterology Private Limited, preferential issue (share swap), and rights issue of securities. - Trading window closed from July 1, 2026, until 48 hours post Q1 FY27 results.

- Board of Directors approved the appointment of Mr. Bidari Kotresh Anilkumar as an Additional Director, designated as Executive Director. - The appointment is effective from July 4, 2026, for a term of three years, subject to approval by the members of the company.

- Arvaya Healthcare Limited appointed Mr. Bidari Kotresh Anilkumar as an Additional Director, designated as Executive Director. - The appointment is effective from July 4, 2026, for a term of three years, subject to shareholder approval. - Mr. Anilkumar is a medical professional with over 12 years of leadership experience in healthcare operations.

- Board Meeting on July 04, 2026, to consider appointing Mr. Bidari Kotresh Anilkumar as an Additional Director (Executive). - Trading window closed from July 01, 2026, until 48 hours after the declaration of Q1 FY27 unaudited financial results.

- Arvaya Healthcare Limited received BSE approval for reclassification of four individuals (Ashok Kumar Patawari, Ashim Kumar Patawari, Shweta Patawari, Sushila Devi Patawari) from the 'promoter and promoter group' to the 'public' category. - These individuals held 0 shares and 0% shareholding. - The overall promoter and public shareholding percentages remain unchanged at 30.62% and 69.38% respectively.

- Trading window for Designated Persons to close from July 1, 2026, until 48 hours after Q1 FY27 results declaration. - This is in compliance with SEBI (PIT) Regulations, 2015. - PANs of Designated Persons and their relatives will be frozen during this period.

- Consolidated Revenue ₹9.11 Cr vs ₹0.0036 Cr (▲253047% YoY) - EBITDA ₹1.39 Cr vs ₹-0.19 Cr (▲832% YoY) - PAT ₹1.47 Cr vs ₹-0.21 Cr (▲800% YoY) - EBITDA Margin 15.25% vs -5277.78% (▲529303 bps YoY) - Corrigendum issued for an inadvertent error in Earnings Per Share (EPS) for the quarter and year ended March 31, 2026. - Company's name changed from Bijoy Hans Limited to Arvaya Healthcare Limited with effect from May 11, 2026. - Authorized Share Capital increased from ₹60 Cr to ₹200 Cr, approved on March 17, 2026. - Acquired 100% equity of three subsidiaries (Health Secure Hospitals, Arvaya Health and Wellness, Tec-Pool Solutions) for a total consideration of ₹60.65 Cr during FY26. - Noted ongoing litigation related to claims from medical consultants amounting to ₹3.72 Cr, with management expecting a favorable outcome.

- Corrigendum filed for an inadvertent error in Earnings Per Share (EPS) for the quarter and year ended March 31, 2026. - Consolidated Operating Revenue for Q4 FY26 was ₹911.33 Lacs vs ₹0.36 Lacs in Q4 FY25 (▲252991.67% YoY). - Consolidated EBITDA for Q4 FY26 was ₹138.95 Lacs, a significant turnaround from a loss of (₹18.81) Lacs in Q4 FY25. - Consolidated Net Profit (PAT) for Q4 FY26 was ₹146.76 Lacs, a significant turnaround from a loss of (₹20.52) Lacs in Q4 FY25. - EBITDA Margin improved significantly from negative in Q4 FY25 to 15.25% in Q4 FY26. - Company name changed from "Bijoy Hans Limited" to "Arvaya Healthcare Limited" effective May 11, 2026. - Acquired 100% equity of three subsidiaries (Health Secure Hospitals, Arvaya Health and Wellness, Tec-Pool Solutions Private Limited) for a total consideration of ₹60.65 Crores during FY26, materially changing the company's composition and contributing significantly to financial results. - Ongoing litigation/arbitration proceedings related to claims by medical consultants amounting to ₹37.22 Crores, though management believes the probability of ruling in the company's favor is high.

- Corrigendum issued for an inadvertent error in Earnings Per Share (EPS) in the Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2026. - Standalone Total Income ₹6.61 Lacs vs ₹5.08 Lacs (▲30.1% YoY) - EBITDA ₹(63.35) Lacs vs ₹(14.09) Lacs (Loss increased significantly YoY) - PAT ₹(63.35) Lacs vs ₹(20.52) Lacs (Loss increased by 208.7% YoY)

Arvaya Healthcare Limited notified that due to an increase in its paid-up equity share capital on March 4, 2026, it no longer qualifies for the exemption under Regulation 15(2)(a) of SEBI LODR Regulations. Consequently, enhanced corporate governance provisions, including the Annual Secretarial Compliance Report, are now applicable. The company is taking necessary steps to comply within six months from the date of exceeding the threshold limit.

Arvaya Healthcare Limited reported Audited Standalone Financial Results for Q4 FY26. Total Income for the quarter was ₹6.61 Lacs, a ▲30.12% YoY increase from ₹5.08 Lacs. However, the company's EBITDA loss significantly widened to ₹69.96 Lacs from ₹18.81 Lacs in Q4 FY25. Net Loss (PAT) also widened to ₹63.35 Lacs from ₹20.52 Lacs YoY. The board also noted the resignation of its Internal Auditor and approved a new appointment.

Arvaya Healthcare Limited's Board Meeting on May 28, 2026, approved audited financial results (Standalone and Consolidated) for Q4 and FY ended March 31, 2026, with an unmodified audit opinion. Key updates include the company's name change from Bijoy Hans Limited, an increase in authorized share capital from ₹60 Cr to ₹200 Cr, and the acquisition of three subsidiaries (Health Secure Hospitals, Arvaya Health and Wellness, Tec-Pool Solutions) for approximately ₹606.5 Cr. These acquisitions, effective March 4, 2026, significantly change the company's composition. An internal auditor resigned and a new one was appointed.

Arvaya Healthcare Limited reported Standalone Revenue from operations ₹0.00 Lacs vs ₹0.36 Lacs (▼100% YoY), EBITDA ₹(69.96) Lacs vs ₹(18.81) Lacs (loss widened), PAT ₹(63.35) Lacs vs ₹(20.52) Lacs (loss widened). EBITDA Margin not meaningful due to negative EBITDA. The Board also noted the resignation of Mr. Aslesh Ramchandra Parannawar as Internal Auditor and appointed M/s. G K Vora & Co. as replacement.

Arvaya Healthcare Limited announced a Board Meeting to be held on Thursday, May 28, 2026, to consider and approve the Audited Financial Statements (Standalone and Consolidated) for the Fourth Quarter and Year Ended March 31, 2026. The trading window for dealing in shares remains closed from April 01, 2026, to May 30, 2026.